Literature DB >> 31313117

Medicare Spending on Drugs and Biologics Not Recommended for Coverage by International Health Technology Assessment Agencies.

Alexander C Egilman1,2, Joshua D Wallach1,2,3, Sanket S Dhruva4, Gregg S Gonsalves1,5, Joseph S Ross6,7,8,9,10.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31313117      PMCID： PMC6848610          DOI： 10.1007/s11606-019-05149-6

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN： 0884-8734            Impact factor:   6.473


× No keyword cloud information.
  3 in total

1.  Medicare and cost-effectiveness analysis.

Authors:  Peter J Neumann; Allison B Rosen; Milton C Weinstein
Journal:  N Engl J Med       Date:  2005-10-06       Impact factor: 91.245

2.  Health technology assessment in the United States.

Authors:  Bryan Luce; Rebecca Singer Cohen
Journal:  Int J Technol Assess Health Care       Date:  2009-06-09       Impact factor: 2.188

3.  Paying for Prescription Drugs Around the World: Why Is the U.S. an Outlier?

Authors:  Dana O Sarnak; David Squires; Greg Kuzmak; Shawn Bishop
Journal:  Issue Brief (Commonw Fund)       Date:  2017-10-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.